JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform rating and a $3 price target. Factive prescriptions for the week ended Dec. 2 were 6,065, (5,889 new prescriptions), representing 0.81% of the weekly prescriptions for the quinolone class of antibiotics. That compares to 4,544 total prescriptions (4,379 new scripts) in the previous week. Total Testim prescriptions for the week ended Dec. 2 were 5,325 compared with 4,180 prescriptions in the previous week ending Nov. 25. Shares of the Waltham, Mass., pharmaceutical company were up 5 cents, or 2.34%, at $2.19 on volume of 673,419 shares versus the three-month running average of 552,540 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.